Acquired Company

Dianthus Therapeutics, Inc. completed its merger with Magenta Therapeutics, Inc. on 9/11/2023, after which the combined company began trading under the ticker DNTH.

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients. Show more

100 Technology Sq Fl 5, Massachusetts, 02139-3585, US

www.magentatx.com

Research and Development in Biotechnology

Professional, Scientific, and Technical Services

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$0.76

Open

$0.71

Volume

376,060

Day Range

$0.68 - $0.76

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

2.23%

Institutional Own.

62.64%

Qtr Updated

03/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MGTA-145 + plerixafor Details Sickle cell disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MGTA-456 Details Leukemia, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.